JMP Securities analyst Jonathan Wolleben raised the firm’s price target on Protagonist Therapeutics to $35 from $28 and keeps an Outperform rating on the shares. Protagonist’s detailed Phase 2b data unveiled at the World Congress of Dermatology support JNJ-2113 as the most efficacious oral agent in development for psoriasis, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PTGX:
- 3 Best Stocks to Buy Now, 7/6/2023, According to Top Analysts
- Biotech Alert: Searches spiking for these stocks today
- J&J FRONTIER 1 Phase 2 leaves door open for Ventyx’s VTX-958, says Oppenheimer
- Wells Fargo expects Ventyx Biosciences’ shares to work into 2H23 catalysts
- Protagonist data suggests ‘very strong profile’ for JNJ-2113, says Jefferies
